Trials / Unknown
UnknownNCT02075086
Angiogenic Switch in Patients With Colorectal Cancer
Angiogenic Switch as Predictor of Response to Chemotherapy in Patients With Metastatic Colorectal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Grupo Hospital de Madrid · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
A group of colorectal cancer (CRC) patients treated with chemotherapy and Bevacizumab (Bev) maintain the same sensitivity after progression to maintenance treatment because they remain dependent on VEGF angiogenic mediator, while other patients in whom there is an angiogenic switch (AS) become dependent on other angiogenic cytokines and become resistant to Bev chemotherapy combinations .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Xelox or Xeliri Bevacizumab | Chemotherapy treatment |
Timeline
- Start date
- 2011-07-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2014-03-03
- Last updated
- 2015-03-17
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT02075086. Inclusion in this directory is not an endorsement.